KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2017 - 2018)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Accumulated Expenses for 4 consecutive years, with $23.6 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Other Accumulated Expenses rose 117.66% year-over-year to $23.6 million, compared with a TTM value of $23.6 million through Dec 2018, up 117.66%, and an annual FY2018 reading of $23.6 million, up 117.66% over the prior year.
  • Other Accumulated Expenses was $23.6 million for Q4 2018 at Alnylam Pharmaceuticals, up from $10.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $25.4 million in Q1 2014 and bottomed at $3.8 million in Q4 2014.
  • Average Other Accumulated Expenses over 3 years is $15.9 million, with a median of $17.2 million recorded in 2017.
  • The sharpest move saw Other Accumulated Expenses increased 16.6% in 2014, then surged 117.66% in 2018.
  • Year by year, Other Accumulated Expenses stood at $3.8 million in 2014, then soared by 185.14% to $10.9 million in 2017, then soared by 117.66% to $23.6 million in 2018.
  • Business Quant data shows Other Accumulated Expenses for ALNY at $23.6 million in Q4 2018, $10.9 million in Q4 2017, and $3.8 million in Q4 2014.